Board of Directors
We are eager to answer them. Call us directly or submit the convenient online form below.
Daniel R. Omstead, M.S, Ph.D – Chairman of the Board
Daniel R. Omstead, Ph.D., is President and Chief Executive Officer of Tekla Capital Management LLC. He is also President of Tekla Healthcare Investors, Tekla Life Sciences Investors, Tekla Healthcare Opportunities Fund and Tekla World Healthcare Fund, four NYSE listed closed-end mutual funds that make equity investments in healthcare-related companies. Prior to joining Tekla, Dan was President and CEO of Reprogenesis, Inc. a private development stage biotech company developing therapies in the field of regenerative medicine. In 2000, Reprogenesis was merged with two other biotech companies to form Curis, Inc. Before joining Reprogenesis, Dr. Omstead was Senior Vice President, Research and Development at Cytotherapeutics, Inc a public biotech company that developed CNS therapies. Prior to entering the biotech industry, Dan was employed for fourteen years in the pharmaceutical industry at Ortho Pharmaceutical Corporation and at the R.W. Johnson Pharmaceutical Research Institute, both divisions of Johnson and Johnson and at Merck Sharpe and Dohme Research Laboratories, a division Merck and Company, Inc. While at J&J, Dan participated in the development of Orthoclone OKT3™, Eprex™/Procrit™ and other biological products. While at Merck, he worked on the development of Recombivax™, Mefoxin™, Heartguard™ and other traditional drug products. Dan holds Doctoral and Master’s Degrees in Chemical Engineering and Applied Chemistry from Columbia University and a B.S. degree in Civil Engineering from Lehigh University.
Jeff Elkins – President and Chief Executive Officer
With almost 30 years of medical device experience across a range of operational roles, Jeff Elkins will now lead VENITI. He was most recently COO (and CEO prior to their US commercial launch) of Aptus Endosystems, acquired by Medtronic, and prior to that, founding COO and CEO of FlowMedica, acquired by AngioDynamics. Jeff was previously the CTO for World Medical Corp where he lead the development and scale-up of the TALENT aortic endograft system, acquired by Medtronic, then assumed the role of Vice President and Business Unit Manager for the Endovascular Division of Medtronic. He also held various Operations and Product Development management positions at Cordis and Cordis Endovascular Systems (acquired by J&J), as well as Haemonetics Corp. during their IPO. Jeff has a BS in Mechanical Engineering from the University of Massachusetts, Amherst.
Michael Liang, Ph.D.
Michael Liang joined Baird Capital in 2006 and concentrates on healthcare investments. Prior to joining Baird Capital, Mike was a venture investor with Advent Venture Partners and before that, served in an operating role as a Director of R&D at Cortek, a spinal orthopedics company. Mike is currently a member of the board of directors of Amphora Medical, GenomeDx Biosciences, Insightra Medical, Veniti, and Zurex Pharma, serving as Chairman of the Board for Insightra Medical and Veniti. He was previously a board member of Interlace Medical before its acquisition in 2011 and a board observer of TomoTherapy before its public offering. Mike is a member of the advisory board for the University of Illinois Chicago’s Proof of Concept Fund, Northwestern University’s Innovation and New Ventures Office, the Wisconsin Alumni Research Foundation (WARF) Accelerator program, and the governance board for the Chicago Biocenter initiative, MATTER. Mike also is a member of Rush University Medical Center’s Associates Board. Mike received a BS from the University of California Berkeley, a Ph.D. in biophysical chemistry from Stanford University and conducted a postdoctoral fellowship at Harvard University.
Tom Duerig, Ph.D.
Tom Duerig received his B.S. in physics from Lehigh University and his Ph.D. in Materials Science from Carnegie-Mellon. He began working on shape memory alloys in 1980 at the Brown-Boveri research center in Baden, Switzerland. In 1983 he relocated to Silicon Valley, continuing his research of shape memory alloys with Raychem Corporation. In 1991, he founded Nitinol Devices & Components, Inc. (NDC), with a focus on medical applications for Nitinol. After NDC was acquired by Johnson & Johnson in 1997, he served as a president of J&J for eleven years before leading a management buy-out of NDC in 2008. NDC is now an independent, privately owned company with over 500 employees. In 1993, Tom founded the Society of Superelastic and Shape Memory Technologies (SMST). He has published over 100 articles and authored the novel, Stan’s Leap, iUniverse, 2005.
Glen A. Kashuba
Mr. Kashuba is currently the Chief Executive Officer of Cerapedics, Inc., a privately held ortho-biologics company focused on developing and commercializing novel “peptide-enhanced” bone graft products for the $1.8B orthopedics marketplace. He has over 27 years of experience in the medical device industry. Prior to his current position, Mr. Kashuba served as Worldwide President for Spine & Bone Healing Technologies, Inc., a division of Biomet Inc.; and concurrently served as Senior Vice President on Biomet’s Worldwide Operating Board, encompassing their Orthopedics, Spine, Trauma, Biologics, and Sports Medicine businesses. During his tenure at Johnson & Johnson, he served as Worldwide President for Cordis Endovascular and Neurovascular and Codman Neurosciences. Prior to his position at Codman, he was U.S. President of DePuy Spine. In addition to his corporate roles, Mr. Kashuba concurrently managed a successful contract manufacturing business that was sold to Paragon Medical in 2005. Mr. Kashuba has been active on a number of medical device and venture boards, including Cambridge Endoscopic Devices, Palyon Medical, SpineView, and VENITI, Inc. He is currently Entrepreneur in Residence at PTV Sciences, a leading healthcare venture capital firm, and also serves as advisor to Baird Venture Partners, MedCap Advisors, and Volcano Capital. Mr. Kashuba has a B.S. in Industrial Engineering from Rutgers University, and completed postgraduate work in finance and bioengineering at the Harvard Business School, Clemson University, and the New Jersey Institute of Technology.